Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Lyra Therapeutics, Inc. - Common Stock (NQ:LYRA)

0.4950 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lyra Therapeutics, Inc. - Common Stock

News headline image
Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update
From Lyra Therapeutics, Inc.
Via Business Wire
News headline image
Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
From Lyra Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.